191 related articles for article (PubMed ID: 30774412)
1. Phosphate binder pill burden, adherence, and serum phosphorus control among hemodialysis patients converting to sucroferric oxyhydroxide.
Gray K; Ficociello LH; Hunt AE; Mullon C; Brunelli SM
Int J Nephrol Renovasc Dis; 2019; 12():1-8. PubMed ID: 30774412
[TBL] [Abstract][Full Text] [Related]
2. Sucroferric Oxyhydroxide as Part of Combination Phosphate Binder Therapy among Hemodialysis Patients.
Molony DA; Parameswaran V; Ficociello LH; Mullon C; Kossmann RJ
Kidney360; 2020 Apr; 1(4):263-272. PubMed ID: 35372921
[TBL] [Abstract][Full Text] [Related]
3. Sucroferric Oxyhydroxide in Maintenance Hemodialysis: A Retrospective, Comparative Cohort Study.
Coyne DW; Ficociello LH; Parameswaran V; Rosen MM; Mullon C; Kossmann RJ; Sprague SM
Kidney Med; 2020; 2(3):307-316. PubMed ID: 32734250
[TBL] [Abstract][Full Text] [Related]
4. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.
Floege J; Covic AC; Ketteler M; Mann J; Rastogi A; Spinowitz B; Rakov V; Lisk LJ; Sprague SM
Nephrol Dial Transplant; 2017 Nov; 32(11):1918-1926. PubMed ID: 28339993
[TBL] [Abstract][Full Text] [Related]
5. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence.
Coyne DW; Sprague SM; Vervloet M; Ramos R; Kalantar-Zadeh K
J Nephrol; 2022 Apr; 35(3):875-888. PubMed ID: 35138627
[TBL] [Abstract][Full Text] [Related]
6. Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study.
Kalantar-Zadeh K; Ficociello LH; Parameswaran V; Athienites NV; Mullon C; Kossmann RJ; Coyne DW
BMC Nephrol; 2019 Oct; 20(1):396. PubMed ID: 31664928
[TBL] [Abstract][Full Text] [Related]
7. One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis.
Kendrick J; Parameswaran V; Ficociello LH; Ofsthun NJ; Davis S; Mullon C; Kossmann RJ; Kalantar-Zadeh K
J Ren Nutr; 2019 Sep; 29(5):428-437. PubMed ID: 30679076
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
Floege J; Covic AC; Ketteler M; Mann JF; Rastogi A; Spinowitz B; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
Nephrol Dial Transplant; 2015 Jun; 30(6):1037-46. PubMed ID: 25691681
[TBL] [Abstract][Full Text] [Related]
9. Management of serum phosphorus over a 1-year follow-up in patients on peritoneal dialysis prescribed sucroferric oxyhydroxide as part of routine care: a retrospective analysis.
Kalantar-Zadeh K; Ficociello LH; Zhou M; Anger MS
BMC Nephrol; 2024 Jun; 25(1):197. PubMed ID: 38886636
[TBL] [Abstract][Full Text] [Related]
10. The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis.
Ramos R; Chazot C; Ferreira A; Di Benedetto A; Gurevich K; Feuersenger A; Wolf M; Arens HJ; Walpen S; Stuard S
BMC Nephrol; 2020 Dec; 21(1):530. PubMed ID: 33287733
[TBL] [Abstract][Full Text] [Related]
11. Serum Phosphorus and Pill Burden Among Hemodialysis Patients Prescribed Sucroferric Oxyhydroxide: One-Year Follow-Up on a Contemporary Cohort.
Kendrick JB; Zhou M; Ficociello LH; Parameswaran V; Mullon C; Anger MS; Coyne DW
Int J Nephrol Renovasc Dis; 2022; 15():139-149. PubMed ID: 35431567
[TBL] [Abstract][Full Text] [Related]
12. Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide.
Kalantar-Zadeh K; Parameswaran V; Ficociello LH; Anderson L; Ofsthun NJ; Kwoh C; Mullon C; Kossmann RJ; Coyne DW
Am J Nephrol; 2018; 47(3):153-161. PubMed ID: 29514139
[TBL] [Abstract][Full Text] [Related]
13. A real-world analysis of the influence of age on maintenance hemodialysis patients: managing serum phosphorus with sucroferric oxyhydroxide as part of routine clinical care.
Rhee CM; Zhou M; Woznick R; Mullon C; Anger MS; Ficociello LH
Int Urol Nephrol; 2023 Feb; 55(2):377-387. PubMed ID: 35953565
[TBL] [Abstract][Full Text] [Related]
14. Serum Phosphorus Management with Sucroferric Oxyhydroxide as a First-Line Phosphate Binder within the First Year of Hemodialysis.
Medaura JA; Zhou M; Ficociello LH; Anger MS; Sprague SM
Am J Nephrol; 2024; 55(2):127-135. PubMed ID: 38091973
[TBL] [Abstract][Full Text] [Related]
15. Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis.
Wang S; Alfieri T; Ramakrishnan K; Braunhofer P; Newsome BA
Nephrol Dial Transplant; 2014 Nov; 29(11):2092-9. PubMed ID: 24009281
[TBL] [Abstract][Full Text] [Related]
16. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
[TBL] [Abstract][Full Text] [Related]
17. Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data
.
Coyne DW; Ficociello LH; Parameswaran V; Anderson L; Vemula S; Ofsthun NJ; Mullon C; Maddux FW; Kossmann RJ; Sprague SM
Clin Nephrol; 2017 Aug; 88(8):59-67. PubMed ID: 28587714
[TBL] [Abstract][Full Text] [Related]
18. Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients.
Akizawa T; Sato Y; Ikejiri K; Kanda H; Fukagawa M
Kidney Int Rep; 2021 Sep; 6(9):2371-2380. PubMed ID: 34514198
[TBL] [Abstract][Full Text] [Related]
19. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
20. A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis.
Bousher A; Al-Makki A; Sutton J; Shepler B
Clin Ther; 2014 Dec; 36(12):2082-2093. PubMed ID: 25450474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
